<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705506</url>
  </required_header>
  <id_info>
    <org_study_id>186/60</org_study_id>
    <nct_id>NCT04705506</nct_id>
  </id_info>
  <brief_title>Gemigliptin and Biomarkers of Kidney Injury and Vascular Calcification</brief_title>
  <official_title>Effect of Gemigliptin on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Nephropathy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangkok Metropolitan Administration Medical College and Vajira Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangkok Metropolitan Administration Medical College and Vajira Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control and contain pleiotropic&#xD;
      actions on kidney injury, albuminuria and vascular inflammation especially in animal models.&#xD;
      We plan to evaluate the efficacy of potent DPP4-inhibitors (gemigliptin) in response to these&#xD;
      aspects in diabetic nephropathy patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, randomized, placebo-controlled trial. A total of 201&#xD;
      participants were enrolled and randomly assigned to gemigliptin 50 mg daily and standard care&#xD;
      of diabetes mellitus for 6 months. The changes of coronary calcium score (CAC score),&#xD;
      cardio-ankle vascular index (CAVI), estimated glomerular filtration rate (GFR), markers of&#xD;
      vascular calcification and markers of tubular renal injury were evaluated at baseline and 6&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2017</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center, prospective, randomized, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Markers of renal injury</measure>
    <time_frame>6 months</time_frame>
    <description>urine NGAL/Cr,urine Kim-1/Cr,urine LFABP/Cr (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of vascular calcification</measure>
    <time_frame>6 months</time_frame>
    <description>serum bone alkaline phosphatase(pg/mL),osteopontin (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of renal injury</measure>
    <time_frame>6 months</time_frame>
    <description>Protienuria (mg/day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of renal injury</measure>
    <time_frame>6 months</time_frame>
    <description>eGFR (mL/min/1.73m2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of vascular calcification</measure>
    <time_frame>6 months</time_frame>
    <description>Reactive oxygen species (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of vascular calcification</measure>
    <time_frame>6 months</time_frame>
    <description>CAVI,CAC score(unit) ,CAVI normal less than8 ,CAC score normal less than 100</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Gemigliptin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive gemigliptin 50 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control received standard care of diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <description>We collected baseline data from all participants for demographic characteristics,comorbid conditions and biochemistry indexes.The biomarkers for vascular calcification and renal injury were collected.Baseline CAC score and CAVI were done.The patients then were randomized into 2 groups: Group 1 received gemigliptin 50 mg /day for 6 months in addition to standard treatment ,Group 2 will have standard treatment for diabetes mellitus (DM) and chronic kidney disease (CKD).The patients will be followed up every eight weeks.Fasting plasma glucose ,BUN creatinine and 24 hour urine protein were measured at each study visit.Patients were scheduled for follow-up visits at months 2,4,and 6.After 6 months ,all the blood tests,CAC score and CAVI will be done again.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Gemigliptin group</arm_group_label>
    <other_name>Treatment group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CKD stage 1-3 (eGFR 15-60 ml/min/1.73mL)&#xD;
&#xD;
          -  Non-insulin dependent diabetes mellitus , blood glucose level 30-250 mg/dL&#xD;
&#xD;
          -  Had clinical features compatible with diabetic nephropathy (urine micro albuminuria &gt;&#xD;
             30 g/g creatinine or has evidence of diabetic retinopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to DPP4-inhibitor&#xD;
&#xD;
          -  Concurrent infectious disease&#xD;
&#xD;
          -  Inflammatory diseases&#xD;
&#xD;
          -  Post kidney transplantation&#xD;
&#xD;
          -  Receiving cinacalcet, bisphosphonate ,previously treated with DPP4-Inhibitors and&#xD;
             sodium-glucose cotransporter-2 inhibitor (SGLT2-i).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thananda Trakarnvanich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navamindradhiraj University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine ,Vajira Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2 Division of Nephrology,Department of Medicine Pramongkutklao Hospital and College of Medicine,Thailand</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine,Police General Hospital,Thailand</name>
      <address>
        <city>Bangkok</city>
        <zip>10500</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 9, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangkok Metropolitan Administration Medical College and Vajira Hospital</investigator_affiliation>
    <investigator_full_name>Thananda Trakarnvanich</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gemigliptin</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>Vascular Calcification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

